Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
The GH and IGF-1 axis is a candidate disease-modifying target in nonalcoholic fatty liver disease (NAFLD) given its lipolytic, anti-inflammatory and anti-fibrotic properties. IGF-1 receptor (IGF-1R) and GH receptor (GHR) expression in adult, human hepatic tissue is not well understood across the spe...
Gespeichert in:
| Veröffentlicht in: | Growth hormone & IGF research 2022-08, Vol.65, p.101482-101482, Article 101482 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101482 |
|---|---|
| container_issue | |
| container_start_page | 101482 |
| container_title | Growth hormone & IGF research |
| container_volume | 65 |
| creator | Osganian, Stephanie A. Subudhi, Sonu Masia, Ricard Drescher, Hannah K. Bartsch, Lea M. Chicote, Mark L. Chung, Raymond T. Gee, Denise W. Witkowski, Elan R. Bredella, Miriam A. Lauer, Georg M. Corey, Kathleen E. Dichtel, Laura E. |
| description | The GH and IGF-1 axis is a candidate disease-modifying target in nonalcoholic fatty liver disease (NAFLD) given its lipolytic, anti-inflammatory and anti-fibrotic properties. IGF-1 receptor (IGF-1R) and GH receptor (GHR) expression in adult, human hepatic tissue is not well understood across the spectrum of NAFLD severity. Therefore, we sought to investigate hepatic IGF-1R and GHR expression in subjects with NAFLD utilizing gene expression analysis (GEA) and immunohistochemistry (IHC).
GEA (n = 318) and IHC (n = 30) cohorts were identified from the Massachusetts General Hospital NAFLD Tissue Repository. GEA subjects were categorized based on histopathology as normal liver histology (NLH), steatosis only (Steatosis), nonalcoholic steatohepatitis (NASH) without fibrosis (NASH F0), and NASH with fibrosis (NASH F1–4) with GEA by the Nanostring nCounter assay. IHC subjects were matched for age, body mass index (BMI), sex, and diabetic status across three groups (n = 10 each): NLH, Steatosis, and NASH with fibrosis (NASH F1–3). IHC for IGF-1R, IGF-1 and GHR was performed on formalin-fixed, paraffin-embedded hepatic tissue samples.
IGF-1R gene expression did not differ across NAFLD severity while IGF-1 gene expression decreased with increasing NAFLD severity, including when controlled for BMI and age. GHR expression did not differ by severity of NAFLD based on GEA or IHC.
IGF-1R and GHR expression levels were not significantly different across NAFLD disease severity. However, expression of IGF-1 was lower with increasing severity of NAFLD. These findings implicate the GH/IGF-1 axis as a potential target in the treatment of NAFLD and NASH.
•GH and IGF-1 have been implicated in the pathogenesis of NAFLD.•Lower IGF-1 expression is associated with more severe NAFLD.•Expression of IGF-1 and GH receptors is unchanged with increasing severity of NAFLD.•The GH/IGF-1 axis is a potential therapeutic target in NAFLD. |
| doi_str_mv | 10.1016/j.ghir.2022.101482 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9885486</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1096637422000399</els_id><sourcerecordid>2685040718</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-6c34b50f988bd465ed830b98b7abd82c8525ded7a5a439471725ea853177172f3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EoqXwAhyQj1yy-G_iSAgJVe22UiUucLYce9J4lY2D7d3Sx-CNcUgp9MLJM-NvvrHnh9BbSjaU0PrDbnM7-LhhhLGlIBR7hk6p5KxijKvnJSZtXdW8ESfoVUo7QkjLlXiJTrhsFGmoPEU_L37MEVLyYcKhx9fby4riCBbmHCI2k8Pbq7-5n_AAs8ne4uxTOsDSs-Qw5YTvfB7wFCYz2jCEsYh6k_M9Hv0RInY-gUnw2_OJKGUwOay-xfU1etGbMcGbh_MMfbu8-Hp-Vd182V6ff76prJAyV7XlopOkb5XqnKglOMVJ16quMZ1TzCrJpAPXGGkEb0VDGybBKMlps8Q9P0OfVt_50O3B2fKFaEY9R7838V4H4_XTm8kP-jYcdZkohaqLwfsHgxi-HyBlvffJwjiaCcIhaVYrSURZsypStkptDClF6B_HUKIXlnqnF5Z6YalXlqXp3b8PfGz5A68IPq4CKGs6eog62ULCgvOFWNYu-P_5_wJ-yLOo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2685040718</pqid></control><display><type>article</type><title>Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Osganian, Stephanie A. ; Subudhi, Sonu ; Masia, Ricard ; Drescher, Hannah K. ; Bartsch, Lea M. ; Chicote, Mark L. ; Chung, Raymond T. ; Gee, Denise W. ; Witkowski, Elan R. ; Bredella, Miriam A. ; Lauer, Georg M. ; Corey, Kathleen E. ; Dichtel, Laura E.</creator><creatorcontrib>Osganian, Stephanie A. ; Subudhi, Sonu ; Masia, Ricard ; Drescher, Hannah K. ; Bartsch, Lea M. ; Chicote, Mark L. ; Chung, Raymond T. ; Gee, Denise W. ; Witkowski, Elan R. ; Bredella, Miriam A. ; Lauer, Georg M. ; Corey, Kathleen E. ; Dichtel, Laura E.</creatorcontrib><description>The GH and IGF-1 axis is a candidate disease-modifying target in nonalcoholic fatty liver disease (NAFLD) given its lipolytic, anti-inflammatory and anti-fibrotic properties. IGF-1 receptor (IGF-1R) and GH receptor (GHR) expression in adult, human hepatic tissue is not well understood across the spectrum of NAFLD severity. Therefore, we sought to investigate hepatic IGF-1R and GHR expression in subjects with NAFLD utilizing gene expression analysis (GEA) and immunohistochemistry (IHC).
GEA (n = 318) and IHC (n = 30) cohorts were identified from the Massachusetts General Hospital NAFLD Tissue Repository. GEA subjects were categorized based on histopathology as normal liver histology (NLH), steatosis only (Steatosis), nonalcoholic steatohepatitis (NASH) without fibrosis (NASH F0), and NASH with fibrosis (NASH F1–4) with GEA by the Nanostring nCounter assay. IHC subjects were matched for age, body mass index (BMI), sex, and diabetic status across three groups (n = 10 each): NLH, Steatosis, and NASH with fibrosis (NASH F1–3). IHC for IGF-1R, IGF-1 and GHR was performed on formalin-fixed, paraffin-embedded hepatic tissue samples.
IGF-1R gene expression did not differ across NAFLD severity while IGF-1 gene expression decreased with increasing NAFLD severity, including when controlled for BMI and age. GHR expression did not differ by severity of NAFLD based on GEA or IHC.
IGF-1R and GHR expression levels were not significantly different across NAFLD disease severity. However, expression of IGF-1 was lower with increasing severity of NAFLD. These findings implicate the GH/IGF-1 axis as a potential target in the treatment of NAFLD and NASH.
•GH and IGF-1 have been implicated in the pathogenesis of NAFLD.•Lower IGF-1 expression is associated with more severe NAFLD.•Expression of IGF-1 and GH receptors is unchanged with increasing severity of NAFLD.•The GH/IGF-1 axis is a potential therapeutic target in NAFLD.</description><identifier>ISSN: 1096-6374</identifier><identifier>ISSN: 1532-2238</identifier><identifier>EISSN: 1532-2238</identifier><identifier>DOI: 10.1016/j.ghir.2022.101482</identifier><identifier>PMID: 35780715</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Adult ; Fibrosis ; Gene expression analysis ; GH receptor ; Growth hormone (GH) ; Humans ; IGF-1 receptor ; Immunohistochemistry ; Insulin-Like Growth Factor I - genetics ; Insulin-Like Growth Factor I - metabolism ; Insulin-like growth factor-1 (IGF-1) ; Liver - metabolism ; Non-alcoholic Fatty Liver Disease - pathology ; Nonalcoholic fatty liver disease (NAFLD) ; Nonalcoholic steatohepatitis (NASH) ; Receptor, IGF Type 1 - genetics ; Receptor, IGF Type 1 - metabolism</subject><ispartof>Growth hormone & IGF research, 2022-08, Vol.65, p.101482-101482, Article 101482</ispartof><rights>2022</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-6c34b50f988bd465ed830b98b7abd82c8525ded7a5a439471725ea853177172f3</citedby><cites>FETCH-LOGICAL-c455t-6c34b50f988bd465ed830b98b7abd82c8525ded7a5a439471725ea853177172f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ghir.2022.101482$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35780715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Osganian, Stephanie A.</creatorcontrib><creatorcontrib>Subudhi, Sonu</creatorcontrib><creatorcontrib>Masia, Ricard</creatorcontrib><creatorcontrib>Drescher, Hannah K.</creatorcontrib><creatorcontrib>Bartsch, Lea M.</creatorcontrib><creatorcontrib>Chicote, Mark L.</creatorcontrib><creatorcontrib>Chung, Raymond T.</creatorcontrib><creatorcontrib>Gee, Denise W.</creatorcontrib><creatorcontrib>Witkowski, Elan R.</creatorcontrib><creatorcontrib>Bredella, Miriam A.</creatorcontrib><creatorcontrib>Lauer, Georg M.</creatorcontrib><creatorcontrib>Corey, Kathleen E.</creatorcontrib><creatorcontrib>Dichtel, Laura E.</creatorcontrib><title>Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis</title><title>Growth hormone & IGF research</title><addtitle>Growth Horm IGF Res</addtitle><description>The GH and IGF-1 axis is a candidate disease-modifying target in nonalcoholic fatty liver disease (NAFLD) given its lipolytic, anti-inflammatory and anti-fibrotic properties. IGF-1 receptor (IGF-1R) and GH receptor (GHR) expression in adult, human hepatic tissue is not well understood across the spectrum of NAFLD severity. Therefore, we sought to investigate hepatic IGF-1R and GHR expression in subjects with NAFLD utilizing gene expression analysis (GEA) and immunohistochemistry (IHC).
GEA (n = 318) and IHC (n = 30) cohorts were identified from the Massachusetts General Hospital NAFLD Tissue Repository. GEA subjects were categorized based on histopathology as normal liver histology (NLH), steatosis only (Steatosis), nonalcoholic steatohepatitis (NASH) without fibrosis (NASH F0), and NASH with fibrosis (NASH F1–4) with GEA by the Nanostring nCounter assay. IHC subjects were matched for age, body mass index (BMI), sex, and diabetic status across three groups (n = 10 each): NLH, Steatosis, and NASH with fibrosis (NASH F1–3). IHC for IGF-1R, IGF-1 and GHR was performed on formalin-fixed, paraffin-embedded hepatic tissue samples.
IGF-1R gene expression did not differ across NAFLD severity while IGF-1 gene expression decreased with increasing NAFLD severity, including when controlled for BMI and age. GHR expression did not differ by severity of NAFLD based on GEA or IHC.
IGF-1R and GHR expression levels were not significantly different across NAFLD disease severity. However, expression of IGF-1 was lower with increasing severity of NAFLD. These findings implicate the GH/IGF-1 axis as a potential target in the treatment of NAFLD and NASH.
•GH and IGF-1 have been implicated in the pathogenesis of NAFLD.•Lower IGF-1 expression is associated with more severe NAFLD.•Expression of IGF-1 and GH receptors is unchanged with increasing severity of NAFLD.•The GH/IGF-1 axis is a potential therapeutic target in NAFLD.</description><subject>Adult</subject><subject>Fibrosis</subject><subject>Gene expression analysis</subject><subject>GH receptor</subject><subject>Growth hormone (GH)</subject><subject>Humans</subject><subject>IGF-1 receptor</subject><subject>Immunohistochemistry</subject><subject>Insulin-Like Growth Factor I - genetics</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Insulin-like growth factor-1 (IGF-1)</subject><subject>Liver - metabolism</subject><subject>Non-alcoholic Fatty Liver Disease - pathology</subject><subject>Nonalcoholic fatty liver disease (NAFLD)</subject><subject>Nonalcoholic steatohepatitis (NASH)</subject><subject>Receptor, IGF Type 1 - genetics</subject><subject>Receptor, IGF Type 1 - metabolism</subject><issn>1096-6374</issn><issn>1532-2238</issn><issn>1532-2238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxi0EoqXwAhyQj1yy-G_iSAgJVe22UiUucLYce9J4lY2D7d3Sx-CNcUgp9MLJM-NvvrHnh9BbSjaU0PrDbnM7-LhhhLGlIBR7hk6p5KxijKvnJSZtXdW8ESfoVUo7QkjLlXiJTrhsFGmoPEU_L37MEVLyYcKhx9fby4riCBbmHCI2k8Pbq7-5n_AAs8ne4uxTOsDSs-Qw5YTvfB7wFCYz2jCEsYh6k_M9Hv0RInY-gUnw2_OJKGUwOay-xfU1etGbMcGbh_MMfbu8-Hp-Vd182V6ff76prJAyV7XlopOkb5XqnKglOMVJ16quMZ1TzCrJpAPXGGkEb0VDGybBKMlps8Q9P0OfVt_50O3B2fKFaEY9R7838V4H4_XTm8kP-jYcdZkohaqLwfsHgxi-HyBlvffJwjiaCcIhaVYrSURZsypStkptDClF6B_HUKIXlnqnF5Z6YalXlqXp3b8PfGz5A68IPq4CKGs6eog62ULCgvOFWNYu-P_5_wJ-yLOo</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Osganian, Stephanie A.</creator><creator>Subudhi, Sonu</creator><creator>Masia, Ricard</creator><creator>Drescher, Hannah K.</creator><creator>Bartsch, Lea M.</creator><creator>Chicote, Mark L.</creator><creator>Chung, Raymond T.</creator><creator>Gee, Denise W.</creator><creator>Witkowski, Elan R.</creator><creator>Bredella, Miriam A.</creator><creator>Lauer, Georg M.</creator><creator>Corey, Kathleen E.</creator><creator>Dichtel, Laura E.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220801</creationdate><title>Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis</title><author>Osganian, Stephanie A. ; Subudhi, Sonu ; Masia, Ricard ; Drescher, Hannah K. ; Bartsch, Lea M. ; Chicote, Mark L. ; Chung, Raymond T. ; Gee, Denise W. ; Witkowski, Elan R. ; Bredella, Miriam A. ; Lauer, Georg M. ; Corey, Kathleen E. ; Dichtel, Laura E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-6c34b50f988bd465ed830b98b7abd82c8525ded7a5a439471725ea853177172f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Fibrosis</topic><topic>Gene expression analysis</topic><topic>GH receptor</topic><topic>Growth hormone (GH)</topic><topic>Humans</topic><topic>IGF-1 receptor</topic><topic>Immunohistochemistry</topic><topic>Insulin-Like Growth Factor I - genetics</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Insulin-like growth factor-1 (IGF-1)</topic><topic>Liver - metabolism</topic><topic>Non-alcoholic Fatty Liver Disease - pathology</topic><topic>Nonalcoholic fatty liver disease (NAFLD)</topic><topic>Nonalcoholic steatohepatitis (NASH)</topic><topic>Receptor, IGF Type 1 - genetics</topic><topic>Receptor, IGF Type 1 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Osganian, Stephanie A.</creatorcontrib><creatorcontrib>Subudhi, Sonu</creatorcontrib><creatorcontrib>Masia, Ricard</creatorcontrib><creatorcontrib>Drescher, Hannah K.</creatorcontrib><creatorcontrib>Bartsch, Lea M.</creatorcontrib><creatorcontrib>Chicote, Mark L.</creatorcontrib><creatorcontrib>Chung, Raymond T.</creatorcontrib><creatorcontrib>Gee, Denise W.</creatorcontrib><creatorcontrib>Witkowski, Elan R.</creatorcontrib><creatorcontrib>Bredella, Miriam A.</creatorcontrib><creatorcontrib>Lauer, Georg M.</creatorcontrib><creatorcontrib>Corey, Kathleen E.</creatorcontrib><creatorcontrib>Dichtel, Laura E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Growth hormone & IGF research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Osganian, Stephanie A.</au><au>Subudhi, Sonu</au><au>Masia, Ricard</au><au>Drescher, Hannah K.</au><au>Bartsch, Lea M.</au><au>Chicote, Mark L.</au><au>Chung, Raymond T.</au><au>Gee, Denise W.</au><au>Witkowski, Elan R.</au><au>Bredella, Miriam A.</au><au>Lauer, Georg M.</au><au>Corey, Kathleen E.</au><au>Dichtel, Laura E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis</atitle><jtitle>Growth hormone & IGF research</jtitle><addtitle>Growth Horm IGF Res</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>65</volume><spage>101482</spage><epage>101482</epage><pages>101482-101482</pages><artnum>101482</artnum><issn>1096-6374</issn><issn>1532-2238</issn><eissn>1532-2238</eissn><abstract>The GH and IGF-1 axis is a candidate disease-modifying target in nonalcoholic fatty liver disease (NAFLD) given its lipolytic, anti-inflammatory and anti-fibrotic properties. IGF-1 receptor (IGF-1R) and GH receptor (GHR) expression in adult, human hepatic tissue is not well understood across the spectrum of NAFLD severity. Therefore, we sought to investigate hepatic IGF-1R and GHR expression in subjects with NAFLD utilizing gene expression analysis (GEA) and immunohistochemistry (IHC).
GEA (n = 318) and IHC (n = 30) cohorts were identified from the Massachusetts General Hospital NAFLD Tissue Repository. GEA subjects were categorized based on histopathology as normal liver histology (NLH), steatosis only (Steatosis), nonalcoholic steatohepatitis (NASH) without fibrosis (NASH F0), and NASH with fibrosis (NASH F1–4) with GEA by the Nanostring nCounter assay. IHC subjects were matched for age, body mass index (BMI), sex, and diabetic status across three groups (n = 10 each): NLH, Steatosis, and NASH with fibrosis (NASH F1–3). IHC for IGF-1R, IGF-1 and GHR was performed on formalin-fixed, paraffin-embedded hepatic tissue samples.
IGF-1R gene expression did not differ across NAFLD severity while IGF-1 gene expression decreased with increasing NAFLD severity, including when controlled for BMI and age. GHR expression did not differ by severity of NAFLD based on GEA or IHC.
IGF-1R and GHR expression levels were not significantly different across NAFLD disease severity. However, expression of IGF-1 was lower with increasing severity of NAFLD. These findings implicate the GH/IGF-1 axis as a potential target in the treatment of NAFLD and NASH.
•GH and IGF-1 have been implicated in the pathogenesis of NAFLD.•Lower IGF-1 expression is associated with more severe NAFLD.•Expression of IGF-1 and GH receptors is unchanged with increasing severity of NAFLD.•The GH/IGF-1 axis is a potential therapeutic target in NAFLD.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>35780715</pmid><doi>10.1016/j.ghir.2022.101482</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1096-6374 |
| ispartof | Growth hormone & IGF research, 2022-08, Vol.65, p.101482-101482, Article 101482 |
| issn | 1096-6374 1532-2238 1532-2238 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9885486 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Fibrosis Gene expression analysis GH receptor Growth hormone (GH) Humans IGF-1 receptor Immunohistochemistry Insulin-Like Growth Factor I - genetics Insulin-Like Growth Factor I - metabolism Insulin-like growth factor-1 (IGF-1) Liver - metabolism Non-alcoholic Fatty Liver Disease - pathology Nonalcoholic fatty liver disease (NAFLD) Nonalcoholic steatohepatitis (NASH) Receptor, IGF Type 1 - genetics Receptor, IGF Type 1 - metabolism |
| title | Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T12%3A47%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20IGF-1%20receptor%20and%20GH%20receptor%20in%20hepatic%20tissue%20of%20patients%20with%20nonalcoholic%20fatty%20liver%20disease%20and%20nonalcoholic%20steatohepatitis&rft.jtitle=Growth%20hormone%20&%20IGF%20research&rft.au=Osganian,%20Stephanie%20A.&rft.date=2022-08-01&rft.volume=65&rft.spage=101482&rft.epage=101482&rft.pages=101482-101482&rft.artnum=101482&rft.issn=1096-6374&rft.eissn=1532-2238&rft_id=info:doi/10.1016/j.ghir.2022.101482&rft_dat=%3Cproquest_pubme%3E2685040718%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2685040718&rft_id=info:pmid/35780715&rft_els_id=S1096637422000399&rfr_iscdi=true |